Bicara selected the 1,500 mg dose as the go‑forward dose for the FORTIFY‑HNS phase III after phase II data and FDA discussions, targeting substantial enrollment by end‑2026 and an interim analysis by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback